Poietis, a leading bioprinting company, is commercially launching Poieskin, its first bioprinted skin model. The announcement was made by Dr. Fabien Guillemot, President and Scientific Director of Poietis, at the Additive Manufacturing Strategies Conference in Washington, DC; USA, where he participated with a panel of experts at a round table discussion on the future of 3D printing in Medicine.
Poieskin is a model of total human skin made by the Bio-printing of primary human broblasts and collagen for the dermal compartment and primary human keratinocytes for the epidermal compartment. Thanks to the use of Poietis bioprinting platform (consisting of the NGB bio-printer and computer-aided design solutions), Poieskin manufacturing will be very reproducible and flexible, and its features could be also customized. This model will allow the evaluation of cosmetic ingredients and nished products and will strengthen alternative methods to animal testing.
“In order to ensure the reproducibility of manufacturing, the 3D printing of each Poieskin model is precisely controlled, layer by layer, in particular through imaging tools integrated into our NGB bio-printer”. Delphine Fayol, Chief Product Officer.
The first sales of the models will start early April for European customers, and it will be possible to pre-order rst samples of Poieskin® in the coming weeks.
“We are proud that Poietis becomes the rst company to o er for sale a biological tissue model made by bioprinting. It is the realization of several years of R & D by our teams and a major milestone for bioprinting technologies”. Dr. Fabien Guillemot, President and Scientific Director of Poietis.
Poietis is a biotechnology company specializing in the design of regenerative medicine therapies based on 4D laser bio-printing. 4D bio-printing consists of programming tissue self-organization by designing organizations of tissue constituents (cells and extracellular matrix) that evolve in a controlled way until speci c biological functions emerge.
Today, Poietis develops 3D physiological models and establishes partnerships with major pharmaceutical and cosmetic groups such as BASF and L’Oréal. These tissue models allow for more predictive in vitro evaluation of the toxicity and e cacy of drug candidates and new cosmetic ingredients. Its bio-printing technology, for which the company holds the exclusive and worldwide license, is the result of innovative research conducted for ten years by Inserm and the University of Bordeaux.